Jump to content
Search In
  • More options...
Find results that contain...
Find results in...


  • Posts

  • Joined

  • Last visited

2342's Achievements


Newbie (1/14)



  1. Eco artist Edina Tokodi has always been known for her moss graffiti work, but now she has created a portrait for the Fort Green Garden Walk event. Made completely out of succulent plants with white panels atop, the project perfectly create a portrayal of the human face. http://designyearbook.blogspot.com/2009/08/succulent-wall-by-edina-tokodi.html This is incredible!!!
  2. Not be a negative nancy- but we all know we will never see an indicted in our lives……maybe not even in our children’s lives. Too much money, power, corruption and good lawyers……….
  3. 2342


  4. Okay- so I have been reading this post and I have to say- at first- I was pissed off because I was –and- am a total Obama supporter. I consider myself so liberal –that- I make the off the deep end liberal look conservative. THEN- I had an epiphany I thought about the fact that when I first read what Casek had to say- and saw the link- I put my blinders on and would not even click on the link. Basically I have turned into exactly what I loathed about the right wing conservatives – at least- MY PERCEPTION- of right wing conservatives- who sat back and put their blinders on while a nonsensical war transpired in Iraq- torture- rape- extraordinary rendition- and so on. So- there you have it- an over the top- off the deep end- liberal finally realized what is really going on. I still have my doubts though that Obama is worse than Bush- but I have taken off my blinders.
  5. KBR Knowingly Poisoned U.S. Soldiers in Iraq, Refuses to Admit Fault http://cherryhill.injuryboard.com/workplace-injuries/kbr-knowingly-poisoned-us-soldiers-in-iraq-refuses-to-admit-fault.aspx?googleid=258762
  6. HEPATITIS, VIRAL - PAKISTAN: (SINDH) FATAL ****************************************** A ProMED-mail post <http://www.promedmail.org> ProMED-mail is a program of the International Society for Infectious Diseases <http://www.isid.org> Date: Tue 9 Jun 2009 Source: Regional Times [edited] <http://regionaltimes.com/09jun2009/heartlandnews/4person.htm>   4 persons die of hepatitis, 460 other cases reported in New Saeedabad --------------------------------------------------------------------- Due to consumption of contaminated water in village Jan Muhammad Jamali near New Saeedabad [Matiari District, Sindh], 4 people have died, while 460 others have been diagnosed with hepatitis. The Regional Times learnt on Monday [8 Jun 2009] that after an outbreak of diarrhea, which killed 3 persons in village Jan Muhammad Jamali a few days ago, the deadly disease of hepatitis has spread due to consumption of contaminated water. In this regard, it was learnt that 4 villagers have died in a few days, while 460 other hepatitis positive cases have also been reported. However, health department Sindh has decided to establish an emergency hepatitis vaccination camp in village Jan Muhammad Jamali on Tuesday (today [9 Jun 2009]). It is worthwhile to mention that Sindh minister for health has taken serious notice of the matter and directed the EDO [executive district officer] Health to provide better health facilities to the villagers. The Sindh minister for health has also initiated an inquiry into the outbreak of hepatitis and appointed special secretary public health as inquiry officer. The minister also directed the inquiry officer to present a report within 3 days. [byline: Danish Memon] -- Communicated by: ProMED-mail Rapporteur Brent Barrett [This report does not indicate which etiological agent is involved in this hepatitis outbreak. A 2007 report quoted Dr Sharif Ahmad Khan, the national programme manager for prevention and control of hepatitis, who said the percentage of hepatitis B in the country was about 3-4 percent while those infected with hepatitis C reached 5-6 percent. "There are 5 types of hepatitis: A, B, C, D, and E." "Hepatitis A and E occur due to consumption of unhygienic food or contaminated water..." (see ProMED-mail archive no. 20070306.0796). Sindh Province can be located on the map of Pakistan at <http://www.lib.utexas.edu/maps/middle_east_and_asia/pakistan_pol_2002.jpg> The HealthMap/ProMED-mail interactive map of Pakistan can be accessed at <http://healthmap.org/r/00tz>. - Mod.TY] [see also: HIV/AIDS & hepatitis, barbers - Pakistan (Islamabad) 20070521.1630 2007 --- HIV/AIDS & hepatitis, barbers - Pakistan (Islamabad) 20070521.1630 Hepatitis, viral - Pakistan 20070306.0796 2006 ---- Hepatitis B and C, barbers - Pakistan (Islamabad) (02) 20061216.3536 Hepatitis B and C, barbers - Pakistan (Islamabad) 20061215.3529] ...................................dk/ty/mj/dk *##########################################################* ************************************************************ ProMED-mail makes every effort to verify the reports that are posted, but the accuracy and completeness of the information, and of any statements or opinions based thereon, are not guaranteed. The reader assumes all risks in using information posted or archived by ProMED-mail. ISID and its associated service providers shall not be held responsible for errors or omissions or held liable for any damages incurred as a result of use or reliance upon posted or archived material. ************************************************************ Become a ProMED-mail Premium Subscriber at <http://www.isid.org/ProMEDMail_Premium.shtml> ************************************************************ Visit ProMED-mail's web site at <http://www.promedmail.org>. Send all items for posting to: promed@promedmail.org (NOT to an individual moderator). If you do not give your full name and affiliation, it may not be posted. Send commands to subscribe/unsubscribe, get archives, help, etc. to: majordomo@promedmail.org. For assistance from a human being send mail to: owner-promed@promedmail.org. ############################################################ ############################################################
  7. 2342


    Bloody Hell.......... SMALLPOX VACCINATION, ADVERSE EVENTS - USA: PROGRESSIVE VACCINIA ********************************************* A ProMED-mail post <http://www.promedmail.org> ProMED-mail is a program of the International Society for Infectious Diseases <http://www.isid.org> Date: Tue 19 May 2009 Source: CDC. MMWR Morb Mortal Wkly Rep 2009; 58 (early release); 1-4 [edited] <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm58e0519a1.htm?s_cid=rr58e0519a1_e> Progressive vaccinia in a military smallpox vaccinee -- United States, 2009 ---------------------------------------------------------------------- Progressive vaccinia (PV), previously known as vaccinia necrosum, vaccinia gangrenosum, or disseminated vaccinia, is a rare, often fatal adverse event after vaccination with smallpox vaccine, which is made from live vaccinia virus (1). During recent vaccination programs potential cases of PV were investigated, but none met standard case definitions (2). PV has not been confirmed to have occurred in the United States since 1987 (3). On [2 Mar 2009], a US Navy Hospital contacted the Poxvirus Program at CDC to report a possible case of PV in a male military smallpox vaccinee. The service member had been newly diagnosed with acute myelogenous leukemia M0 (AML M0). During evaluation for a chemotherapy-induced neutropenic fever, he was found to have an expanding and nonhealing painless vaccination site 6.5 weeks after receipt of smallpox vaccine. Clinical and laboratory investigation confirmed that the vaccinee met the Brighton Collaboration and CDC adverse event surveillance guideline case definition for PV (4,5). This report summarizes the patient's protracted clinical course and the military and civilian interagency governmental, academic, and industry public health contributions to his complex medical management. The quantities of investigational and licensed therapeutics and diagnostics used were greater than anticipated based on existing smallpox preparedness plans. To support future public health needs adequately, the estimated national supply of therapeutics and diagnostic resources required to care for smallpox vaccine adverse events should be reevaluated. Case description ---------------- On 13 Jan 2009, a healthy service member aged 20 years received a primary smallpox vaccination (ACAM2000 [Acambis, Inc., Cambridge, Massachusetts]) in accordance with the US Department of Defense smallpox vaccination policy*; no other vaccinations were administered that day. Twelve days later, the patient visited a local hospital with fever and headache of one day's duration and was admitted for workup of leukopenia after his white blood cell count was found to be 1400 cells/mm3. On [28 Jan 2009], after transfer to a US Navy tertiary-care facility, he was diagnosed with AML M0. On [30 Jan and 13 Feb 2009], the patient underwent 2 successive rounds of induction chemotherapy with cytarabine, idarubicin, and dexamethasone. Before initial chemotherapy, the vaccination site pustule had a central crust and measured approximately 1 cm [0.4 in] in diameter with minimal surrounding erythema. During the patient's hospital stay from the end of January to the beginning of March [2009], his vaccination site dressing was changed daily. On [2 Mar 2009], during the evaluation of neutropenic fever, the failure of the patient's vaccination site to heal was described. An annular lesion with a deep bulla, raised violaceous leading edge, and a central crust that bled with pressure was noted. The size of the lesion had progressed to approximately 4 x 4 cm [1.6 x 1.6 in] with minimal surrounding erythema or induration. The patient described no pain at the site, although he reported occasional pruritus. A swab of the lesion and serum were sent to CDC for viral and serologic analysis. Viral analysis of the swab by multiple real-time polymerase chain reaction (PCR) assays for orthopoxvirus and vaccinia yielded evidence of viral DNA; viral culture was positive for orthopoxvirus. Serum showed equivocal to absent levels of anti-orthopoxvirus immunoglobulin G (IgG) and immunoglobulin M (IgM) by enzyme-linked immunosorbent assay. The results of the diagnostic testing combined with the patient's medical history met the PV level 1 case definition as defined by the Brighton Collaboration and the confirmed case definition as described by CDC surveillance guidelines (4,5). The criteria met by both case definitions were 1) a documented clinical diagnosis of a disease that is known to be associated with cell-mediated immunodeficiency (in this case AML M0), 2) the primary vaccination site's failure to resolve (in this case more than 6 weeks post vaccination), and 3) the laboratory confirmation of vaccinia virus as the causative agent. On [3 Mar 2009], imiquimod was applied directly to the lesion. Within 24 hours of confirmation of PV on [4 Mar 2009], the patient received licensed Vaccinia Immune Globulin Intravenous (Human) (VIGIV) (Cangene Corporation, Winnipeg, Canada). On [5 Mar and 6 Mar 2009], oral and topical ST-246 (SIGA Technologies, Corvallis, Oregon) were administered under an Emergency Investigational New Drug (E-IND) application. The patient remained stable until the evening of [7 Mar 2009], when he became septic with _Pseudomonas aeruginosa_, likely from a perirectal abscess. He required intubation, maximal vasopressor support, multiple antibiotics, and stress dose corticosteroids. He then developed multiorgan failure and began continuous venovenous hemodialysis. During the next 12 days, the patient slowly stabilized. As a consequence of the duration and amount of vasopressor support, the patient required a bilateral trans-tibial amputation because of dry gangrene of his feet. During [6-19 Mar 2009] the patient received additional oral and topical ST-246 and VIGIV; his ST-246 levels were noted to be lower than those achieved both in healthy subjects in phase I clinical trials and in successful treatment of nonhuman primates with systemic orthopoxvirus disease. The lesion size remained unchanged, but the central crust of the vaccination site sloughed off, followed by most of the outer "ring" flattening, leaving a shallow ulcer with healthy-appearing granulation tissue. During his steroid taper, additional satellite lesions surrounding the vaccination site appeared on [18 Mar 2009], and viral DNA was detected again in the blood. These lesions became vesicular in nature, and on [26 Mar 2009], after a 2nd E-IND was issued, CMX001 (Chimerix, Inc., Research Triangle Park, North Carolina), a lipid conjugate of cidofovir, was administered. From [24 Mar 2009] onward, the satellite and main vaccination site lesions continued to crust, the scabs separated, and underlying tissue epithelialized. Blood viral DNA levels cleared on [29 Mar 2009]. On [10 Apr 2009], the borders of lesions again appeared raised; a shave biopsy grew methicillin-resistant _Staphylococcus aureus_, which responded to antibiotic therapy. The patient received intermittent granulocyte colony-stimulating factor, and his absolute neutrophil and lymphocyte count increased over time. By [1 May 2009], significant portions of the scabs/eschars had fallen off or were removed manually, revealing healthy epidermis. Numerous therapeutics with different biologic mechanisms were used to treat PV in this patient. From [21 Feb 2009] onward, the patient had remained in contact isolation, first for a _Clostridium difficile_ infection and then for his progressive vaccinia infection. On [5 May 2009], contact precautions were discontinued because of the lack of viable virus in lesion specimens from the previous 4 weeks. No cases of contact vaccinia were identified among this patient's health-care workers or close contacts. During [3 Mar-18 May 2009], nearly 200 clinical specimens (lesion and satellite swabs/crusts, ethylenediaminetetraacetic acid [EDTA] blood, bone marrow, and serum) were collected and submitted to CDC to evaluate disease progression and guide therapeutic interventions. After [23 Apr 2009], swabs from satellite lesions or the main vaccination site showed significantly reduced or absent levels of viral DNA, and no viable virus was detected after [2 Apr 2009]. Oropharyngeal sampling and bone marrow biopsies from early and late March [2009], respectively, were negative for vaccinia virus. Orthopoxvirus DNA was detected in EDTA blood at intermittent times during the course of the patient's infection; however, no viable virus was cultured from blood. As of [12 May 2009], the patient had no demonstrable IgM response to orthopoxvirus; IgG levels appeared fully reliant on VIGIV infusion. During [3 Mar-18 May 2009], a total of 20 conference calls to discuss patient status and treatment options were held between the Vaccine Healthcare Centers Network, Military Vaccine Agency (MILVAX), Bureau of Medicine and Surgery of the Navy, CDC, Food and Drug Administration (FDA), National Institutes of Health (NIH), SIGA Technologies, Chimerix, Inc., and academic and health-care professionals. As of [18 May 2009], MILVAX provided 22 and the Strategic National Stockpile (SNS) provided 254 vials of VIGIV used in treatment of this case. [Reported by: E Lederman, MD, H Groff, MD, T Warkentien, MD, A Reese, MD, US Naval Medical Center. D Hruby, PhD, T Bolken, D Grosenbach, PhD, S Yan, PhD, SIGA Technologies, Corvallis, Oregon. W Painter, MD, L Trost, MD, B Lampert, MD, Chimerix, Inc., Research Triangle Park, North Carolina. J Cohen, MD, National Institutes of Health; R Engler, MD, Walter Reed Vaccine Healthcare Center; W Davidson, MPH, S Smith, MS, K Wilkins, Z Braden, Y Li, PhD, I Damon, MD, Div of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, CDC] MMWR editorial note ------------------- Although PV is a rare adverse event (one case per million during routine vaccination during 1963-1968), its case fatality rate in primary US vaccinees was 15 percent despite treatment with massive amounts of VIG (intramuscular) (6). Extensive surgical debridement was sometimes required, even necessitating disarticulation of the arm to "debulk" the amount of infectious material (7). Before smallpox vaccination, patients are screened for numerous contraindications (8). At the time of his vaccination, the patient described in this report did not have any obvious signs or symptoms that would meet any exclusion criteria for vaccination. Training in use of, and careful adherence to, screening tools can identify vaccine candidates at risk for PV and other adverse events (2). Despite this, vaccinees with occult immunodeficiencies might not be recognized, and therefore appropriately deferring vaccination in these persons is not always possible. Lack of inflammation at the expanding vaccination site is the hallmark of PV. Any smallpox vaccinee who has an expanding, nonhealing, painless vaccination site without inflammation for more than 2 weeks should be evaluated for an underlying immunodeficiency, and diagnosis of and treatment for PV should be considered. Health-care providers should report suspected cases of PV or other adverse events to the Vaccine Adverse Event Reporting System (VAERS). Suspected cases of PV also should be reported to state health officials and CDC for clinical consultation and to obtain select therapeutics available only through the SNS. State health departments should call the CDC Emergency Operations Center at 770-488-7100. This patient's protracted clinical course is consistent with previously published cases reports and surveillance summaries. The development of progressive vaccinia, historically observed in patients with cellular immunodeficiencies, often leads to superinfection and subsequent sepsis (that is, fungal, parasitic, and bacterial infections resulting in toxic or septicemic shock, then ultimately death). Past treatment typically included massive doses of VIG, administration of thiosemicarbazone, blood products, and supportive care for accompanying infections (7,9). The improvement of progressive vaccinia in this patient was associated with receipt of VIGIV (the only licensed product for treatment of vaccinia adverse events stockpiled by the SNS), ST-246, and CMX001, and an increase in lymphocyte count. The use of 2 antiviral agents with different mechanisms of action (see note 1) was enabled by the research and development of medical countermeasures for smallpox preparedness activities, as well as the use of the emergency IND process. As of [18 May 2009], the patient had shed nearly all of the scab material on and around the vaccination site. The rapid mobilization of military, CDC, FDA, NIH, drug manufacturer, and academic and health-care human resources to review the case's status and to provide daily, then biweekly laboratory findings that guided treatment recommendations, was enabled by smallpox public health preparedness research and training efforts. Continuing medical education and reinforcement of training related to the prevention, early recognition, and treatment of smallpox vaccine-related adverse events should be part of smallpox vaccination programs. The patient described in this report received VIGIV in the amount originally estimated to treat 30 persons. The extraordinary amounts of VIGIV used to treat this single case of PV underscore the need to reevaluate the adequacy of the national stockpiled supply of this or other medical countermeasures (treatment or prophylactic). Such reevaluation, with additional focus on immunocompromised hosts, will aid in the smallpox vaccination program planning and overall smallpox preparedness efforts. References ---------- 1. CDC: Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR 2003; 52 (No. RR-7) [available at <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5207a1.htm>]. 2. Vellozzi C, Lane JM, Averhoff F, et al: Generalized vaccinia, progressive vaccinia, and eczema vaccinatum are rare following smallpox (vaccinia) vaccination: United States surveillance, 2003. Clin Infect Dis 2005; 41: 689-97 [abstract available at <http://www.ncbi.nlm.nih.gov/pubmed/16080092>]. 3. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS: Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987; 316: 673-6. 4. Nell P, Kohl KS, Graham PL, et al: Progressive vaccinia as an adverse event following exposure to vaccinia virus: case definition and guidelines of data collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25: 5735-44. 5. CDC. Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR 2006; 55 (No. RR-1) [available at <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5501a1.htm>]. 6. Aragon TJ, Ulrich S, Fernyak S, Rutherford GW: Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963-1968. BMC Public Health 2003; 3: 26 [abstract available at <http://www.ncbi.nlm.nih.gov/pubmed/12911836>]. 7. Maurer DM, Harrington B, Lane JM: Smallpox vaccine: contraindications, administration, and adverse reactions. Am Fam Physician 2003; 68: 889-96 [available at <http://www.aafp.org/afp/20030901/889.html>]. 8. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA: Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 2003; 37: 251-71 9. Bray M, Wright ME: Progressive vaccinia. Clin Infect Dis 2003; 36: 766-74 [abstract available at <http://www.ncbi.nlm.nih.gov/pubmed/12627361>]. 10. Quenelle, DC, Prichard MN, Keith KA, et al: Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother 2007; 51: 4118-24 [available at <http://aac.asm.org/cgi/content/full/51/11/4118>]. Note 1. ST-246 prevents viral egress, whereas CMX001 inhibits viral replication, and some data suggest they are synergistic in vitro (10). Note 2. * Information about US Department of Defense policies regarding smallpox vaccination and screening before smallpox vaccination is available at <http://www.smallpox.army.mil>. CDC's clinical evaluation tools for smallpox vaccine adverse reactions are available at <http://emergency.cdc.gov/agent/smallpox/vaccination/clineval>. -- Communicated by: ProMED-mail <promed@promedmail.org> [The essential message of this episode is that future cases of PV likely will require similar intensive and multidisciplinary clinical consultation. Experts with background in vaccine safety, PV treatment, clinical virology, infectious disease, and immunodeficiencies should be engaged. The extraordinary amounts of VIGIV used to treat this single case of PV underscore the need to reevaluate the adequacy of the national stockpiled supply of this or other medical countermeasures (treatment or prophylactic). Such reevaluation, with additional focus on immunocompromised hosts, will aid in the smallpox vaccination program planning and overall smallpox preparedness efforts. The text of the original article (available at the source URL above) is accompanied by graphic images of the progressive vaccinia lesion over a period of 8 weeks. - Mod.CP] [see also: 2003 ---- Smallpox vaccination adverse events - USA (12) 20030712.1716 Smallpox vaccination adverse events - USA (11): few 20030620.1519 Smallpox vaccination adverse events - USA (10) 20030404.0825 Smallpox vaccination adverse events - USA (09) 20030329.0781 Smallpox vaccination adverse events - USA (08) 20030327.0772 Smallpox vaccination adverse events - USA (07) 20030326.0749 Smallpox vaccination, adverse events - USA (06) 20030314.0635 Smallpox vaccination, adverse events - USA (05) 20030311.0592 Smallpox vaccination, adverse events - USA (04) 20030307.0569 Smallpox vaccination, adverse events - USA (03) 20030306.0557 Smallpox vaccination, adverse events - USA (02) 20030306.0556 Smallpox vaccination, adverse events - USA 20030301.0515 Smallpox vaccination, adverse event monitoring - USA 20030206.0324 Smallpox vaccination strategies 20030103.0018] ...................................mpp/cp/mj/mpp *##########################################################* ************************************************************ ProMED-mail makes every effort to verify the reports that are posted, but the accuracy and completeness of the information, and of any statements or opinions based thereon, are not guaranteed. The reader assumes all risks in using information posted or archived by ProMED-mail. ISID and its associated service providers shall not be held responsible for errors or omissions or held liable for any damages incurred as a result of use or reliance upon posted or archived material. ************************************************************ Become a ProMED-mail Premium Subscriber at <http://www.isid.org/ProMEDMail_Premium.shtml> ************************************************************ Visit ProMED-mail's web site at <http://www.promedmail.org>. Send all items for posting to: promed@promedmail.org (NOT to an individual moderator). If you do not give your full name and affiliation, it may not be posted. Send commands to subscribe/unsubscribe, get archives, help, etc. to: majordomo@promedmail.org. For assistance from a human being send mail to: owner-promed@promedmail.org. ############################################################ ############################################################
  8. 2342


    Vaccinations Designed To Sterilize Women? by Kjeld Heising 11-9-7 http://www.clubconspiracy.com/forum/f24/vaccinations-designed-sterilize-women-5619.html Women are being drawn into a medical trap.The outcome is toxication and health erosion. The tool is vaccinations * presented as a solution to "fight" an ever growing number of dangers from the world of microbes. The medical world has got its own Al Qaeda * the invisible army of viruses. With exactly the same attributes: Unknown, being everywhere and nowhere. Invincible. The answer is also approximately the same: More fear, more death. And now, with growing clarity, targeting women. We have for more than a decade had the campaigns for mandatory HIV-tests of pregnant women. Only women. In the Third World, we have had numerous vaccination campaigns targeting women in their fertile age. Only women. Recently, in Denmark, the great drug donor, Bill Gates, has donated USD 10m to a Copenhagen university to further studies on a Malaria vaccine * target group: Women of the Third World. And then, the latest stunt: Vaccination of 12 year old girls in many countries * allegedly against the HPV virus which might (or might not) eventually cause Cervical Cancer. Target group: Girls in the age of just becoming fertile. In some states mandatory, in others just heavily propagandized. What is all this about? Money? Of course but that doesn't account for the focusing on women. Special care for women? Nice. But in fatal opposition to the agenda of "women's lib". Women's lib doesn't include reproduction and is uninterested in the female sex. Could it be ? Yes, it could be exactly the opposite, and I'll tell you why. First, "women's lib" is not a population movement fostered by women being sick-and-tired of oppression. It it a masculine invention, defined in policy papers back from the 1950's, most eagerly promoted by the Rockefeller all-seeing-everywhere-being dynasty and it's political operators. Approximately at the same time when the first feminists surfaced, and already up and run as the project culminated. That happened with the 1974 Henry Kissinger <i>National Security Study Memorandum 200</i> about "the consequences of the global population growth for the US security and overseas interests". This paper, which should be given much much more attention , states that Urgent immediate measures must be taken to reduce fertility. The memo recommends Zero growth rate in the developed countries by 1985 and Zero growth rate in Lesser Developed Countries by 2000. Notice: Defertilization first in the West, then down to the poor. It also recommends the tools. For the industrialized world: Reproductive health - a nicer word for abortion, use of condoms etc. Sex education Improved health Women' equality Day care Government participation Improved social security Reduced infant mortality Well, in Europe, we used to call this "welfare". It now seems, it was just a means to make us stop reproducing ourselves. A great success: Today, we find declining birth rates all over the Western World * only Albania (the poorest country of Europe * no "welfare") is maintaining the size of of its population. The picture becomes clearer when we learn that our Rockefeller-friend John D. the Third back in the 1950's also began advocating that all vaccines should have added Mercury. That served a tripple purpose: Mercury works as a preservative. It can help the chemical industry get rid of a highly toxic waste product (just like Fluoride in toothpaste did). And, most important, the Mercury is absorbed in our body, is not automatically excreted and has various toxic effects. One of the effects is that it destroys the cilia inside the female sex, removing the ability of the mucous membrane to transport men's semen to the egg cells. Which obviously impedes natural conception. Another effect is that children who are born become autistic - the frequency of autistic children increases clearly with the amount of Mercury consumed. And there are other effects of this additive which is called <i>thiomesal</i> - such as diabetes. So, any vaccine containing Mercury, is a defertilization drug. That means almost all vaccines almost all over the world. We get another clue by studying simple facts on HIV and AIDS. As shown in many papers and documentaries, the existence of a virus destroying our immune system has never been documented * to this day it remains a rumour having obsessed most of the medical world and, by being backed up by deeply corrupt statal medical authorities, a fully controlled political layer and a centralized media network loving the "scary setup", it has also obsessed most common people. The facts are that as well as there is no disease-causing HIV virus, there is no test which can prove it's presence in human blood. The so-called HIV-tests test the presence of antibodies and antibodies belong in a functioning immune system. The tests are known to crossreact with many conditions having nothing to do with any particular virus. One of these conditions is you better sit down pregnancy. That's where the AIDS swindle becomes a depopulation tool. For the next step from a positive HIV test is prescription of deadly toxic drugs (charmingly named "Life Prolonging Medication") destroying the immune system and the intestine's ability to absorb nutrients - and causing defective children. These drugs are the most toxic chemicals ever invented by the pharmaceutical industry. In Africa, HIV tests are only performed on pregnancy clinics. And guess where the deadly drugs go. Another clue becomes clear when we look at the WHO vaccination campaigns in the Third World. Most famous are the campaigns from the mid nineties against Tetanus. Despite the fact that 70% of all Tetanus occurred in men, the vaccinations were only given to women. And only women between 14 and 44 years old. The vaccines were mixed with hCG Gonadotropine. Now, hCG is a hormone which is naturally formed in the foetus within the first few days, and which is necessary for it's continued life and growth. When the mixture of vaccine and hCG is inoculated in a woman's blood, her immune defence will not only produce antibodies to the Tetanus bacteria but also to the hCG. As a result, she looses her foetus. These vaccination campaigns were performed on millions and millions of women in Nicaragua, Mexico, Nigeria, Tanzania and the Philippines. Other vaccination campaigns have had other effects. In Uganda, a polio vaccination was performed, killing 600 children in just one month and just one village (Mbarara) - in which there was by coincidence a counting. In Nigeria, polio vaccine was distributed, contaminated with estradiol and a number of carcinogen (cancer generating) agents. How many more of these criminal campaigns have been performed through the years? Then we have the bogus on the Malaria vaccine. Malaria is no microbe disease, so what has a vaccine to do with this? Nothing. But the funny scientist came up with a funny story on a "certain molecule" being necessary for the Malaria parasite to fix on the inside of women's uterus. It's the molecule the vaccine is supposed to target. But only in women. The average age of women getting Cervical Cancer is 50 * as Dr. Tim O'Shea writes in his excellent article "HPV - The First Cancer Vaccine" on Rense.com (http://www.rense.com/general78/hpv.htm). The creator of the HPV vaccine, company Merck, promises an effect-time of five years. So, what the point of vaccinating 12 years old girls? I have no doubt anymore: This has nothing to do with medicine. It has nothing to do with anything based on science. It has nothing to do with diseases. It is a money machine, yes, but it is more. We have another war, and this war is moving from covert to overt. We have a global war on women. ------- Heising is a Danish Men's activist. He can be reached at kjeld@heising.dk
  9. 2342


    I did not want to start a new thread for this- so I posted it here. I have been VERY skeptical of this vaccine since I first read about it- I got this article today from natural news and thought I would share it. 1300 Girls Harmed by HPV Vaccines in UK; Bizarre Side Effects Like Paralysis and Epilepsy http://www.naturalnews.com/z026293.html 1300 Girls Harmed by HPV Vaccines in UK; Bizarre Side Effects Like Paralysis and Epilepsy by David Gutierrez, staff writer (NaturalNews) More than 1,300 girls in the United Kingdom have experienced negative reactions to the government-mandated Cervarix vaccine for the human papillomavirus (HPV), according to adverse events reports collected from doctors by the Medicines and Healthcare products Regulatory Agency (MHRA). "When they introduced this new vaccine, we had major concerns about its safety," said Jackie Fletcher of Jabs, a support group for those negatively affected by vaccines. "The current statistics detailing adverse reactions -- including cases of epilepsy and convulsions -- bears out that we were right to be concerned." Cervarix, manufactured by GlaxoSmithKline, inoculates patients against strains 16 and 18 of HPV, which are believed to be responsible for 70 percent of cervical cancer cases. The British government began a program to vaccinate all secondary school girls in September 2008, and 700,000 have received the injections so far. The government's plan is to have all girls under the age of 18 vaccinated by 2011. Critics have objected, however, that the government based its decision on studies of women under the age of 26, rather than studies conducted on school-age girls. In addition, while the vaccine has been shown to prevent against HPV infection in the short term, there is no evidence of its long-term efficacy or that it actually lowers cancer rates. The MHRA reports show a total of 2,891 adverse events reported in 1,340 girls. The majority were minor and short-lived problems, such as swelling, rashes, pain or mild allergies to the vaccine. A number of cases were more severe, however, including 20 cases of blurred vision, four cases of convulsions, one case of seizures and one epileptic fit. Five cases of partial paralysis were reported, including Bell's palsy (face), Guillain-Barre syndrome (legs), hyopaesthesia (loss of sense of touch) and hemiparesis (severe weakening or paralysis of half the body). "The government needs to look at the future of this program given the number of side-effects coming through," Fletcher said. Sources for this story include: http://www.dailymail.co.uk.
  10. INFLUENZA A (H1N1) - WORLDWIDE (31) *********************************** New H1N1 rumour A ProMED-mail post <http://www.promedmail.org> ProMED-mail is a program of the International Society for Infectious Diseases <http://www.isid.org> In this update: [1] New H1N1 rumour [2] Estimation of R [3] Source of novel H1N1 ****** [1] New H1N1 rumour Date: Fri 15 May 2009 Source: Swine Flu Archives, ScienceInsider, Science [edited] <http://blogs.sciencemag.org/scienceinsider/swine-flu> A New, New H1N1 in Mexico? -------------------------- This odd exchange took place at today's press conference with the US Centers for Disease Control and Prevention (CDC): David Brown, The Washington Post: There's a report that there is yet another new H1N1 virus that has been found in the states of Durango, Zacatecas, and Jalisco that is distinct from both this swine H1N1 and the seasonal Brisbane H1N1. Have you heard of this and can you tell us anything about this? Daniel Jernigan, CDC's deputy director of influenza division: We've heard of some reports about that, but I've not had any direct information about the specifics of that case. There's ongoing dialog between us and the folks that are in Mexico, and as we know more about that, we'll be able to let people know. ScienceInsider is investigating but has yet to learn anything substantive. It was aired in a public venue, though, and likely will receive media attention, regardless of whether it turns out to be false. "We heard a rumor but think it may be a misinterpretation of some lab data by a non-lab person," Nancy Cox, head of CDC's influenza division, tells ScienceInsider. "We are following up." [byline: Jon Cohen] -- communicated by: Kunihiko Iizuka <edcvfr3464@yahoo.co.jp> ****** [2] Date: Thu 14 May 2009 Source: Eurosurveillance, Volume 14, Issue 19, 14 May 2009 [edited] <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19212> Why are Mexican data important? ------------------------------- This issue of Eurosurveillance contains an article by a French team on the transmission of the new influenza A(H1N1) in Mexico, which uses published figures from the outbreak to estimate important parameters for transmission, among them the reproduction rate, R (1). Such studies may have important implications for public health action in Europe. [This article has been reproduced previously in ProMED-mail; see Part [3], Influenza A (H1N1) - worldwide (29) 20090515.1824] What is R? ---------- The growth rate of an epidemic is determined by 2 factors: the number of new persons infected by each case and the time from start of infectiousness in one case to start of infectiousness in the secondary cases caused by him/her. The 1st factor is called "reproduction rate" and is usually denoted R. If the disease is spreading in a population that is totally susceptible the term "basic reproduction rate" (Ro) is used. R is the product of four terms: the risk of transmission in one single contact between an infectious and a susceptible person, the frequency of such contacts in the population, the duration of infectivity of a case, and the proportion of susceptibles in the population. If R is greater than 1 this means that each case infects more than one new person, and the outbreak is likely to continue. If R is less than 1 the outbreak will eventually die out, even if there may be a number of cases before that. The time from infectiousness in one case to infectiousness in his/her secondary cases is called "generation time" (Tg) and is basically a biological constant, even if its exact value depends on how it is estimated. Values for the factors that determine R can be calculated on the basis of scientific knowledge of the disease, its context of transmission, and the immunity status of the population. However, during an epidemic an R value usually has to be derived from the analysis of the epidemic curve or by the study of transmission chains. Several studies have now tried to estimate R (or Ro) and Tg for the new influenza A(H1N1) virus from Mexican data. In the one published in this issue of Eurosurveillance [1], the authors use one exponential fitting and one real-time estimation model to arrive at an estimate of R between 2.2 and 3.1. This is higher than the value found in an article in Science [2], which estimated Ro to be 1.4-1.6 using 3 models: one exponential fitting, one genetic analysis, and 2 standard SIR models for a confined outbreak in La Gloria. Another analysis of the minor genetic changes in the virus over time arrived at a Ro estimate of 1.16 [3]. Why is Ro important in public health? ------------------------------------- The reproduction rate reflects effectiveness of transmission, and therefore has important implications for the efforts that public health authorities would have to make in implementing health measures aiming at containing or mitigating the outbreak. For example, with a Ro of 1.16, preventing 14 per cent of cases will result in eventually interrupting transmission, while with a Ro of 3.1, preventing 68 per cent cases would be needed -- assuming a total random mixing of contacts in the population. Why are Ro estimates so different for influenza? ------------------------------------------------ A few studies have tried to measure Ro for seasonal influenza [4], and found it to be in the order of 1.2 to 1.4. However, for most of the seasonal strains, there is already some immunity in the population from past seasons, which lowers the reproduction rate (and it should thus really not be called Ro in this situation). For any epidemic of a disease that leads to immunity after infection the initial Ro will also be higher than the actual R at any later stage, since the proportion still susceptible in the population will decrease. It should also be realised that delayed reporting of cases will affect an estimate of R; a problem that adheres to the study in this issue and the others cited above. What influences Ro? ------------------- The risk of transmission in a contact when an infective meets a susceptible is basically a biological constant (even if it varies over the time course of the infection), as is the duration of infectiveness. However, frequency of contacts varies considerably between populations and population groups. For example, among children in schools or day care, the contact frequency is higher than among adults [5], and it also varies by culture, by family size in a society, by types of social interaction, etc. Why is the Ro from Mexico important? ------------------------------------ One could question why there is so much interest around studies of R and Ro based on Mexican data. Would they apply to Europe? One could guess that contact density might be higher in a Mexican setting, but on the other hand, since the epidemic has already run its course for some time there, the proportion of non-susceptibles would be higher in Mexico and the European situation would more approach a "true" (higher) Ro, with a totally susceptible population. In a graph [not reproduced here] of the daily reported cumulative number of cases in Mexico, Canada, US and EU/EFTA countries, outbreak of new influenza A(H1N1), April-May 2009, we have just compared the daily reported cumulative number of cases in Mexico, Canada, United States, and European Union and European Free Trade Association (EU / EFTA) countries. On a semi-logarithmic scale it is evident that the slope for Europe is very much the same as for Mexico. It is difficult to estimate the time lag for Europe, but it seems that we are some 1-2 months behind. If the generation times are the same for both epidemics -- which seems highly plausible ***--then an estimate of Ro for Mexico would apply also to Europe. A Ro just above 1 could mean that a containment strategy might be successful. The European Centre for Disease Prevention and Control (ECDC) is continuously monitoring the situation and with more data being available every day in Europe we will obviously be able to have a better picture here soon as well. Nevertheless, the similarities of the shapes of the epidemics indicate that lessons from Mexico could apply also to Europe. References ---------- 1. Boelle PY, Bernillon P, Desenclos JC. A preliminary estimation of the reproduction ratio for new influenza A(H1N1) from the outbreak in Mexico, March-April 2009. Euro Surveill 2009; 14(19): pii=19205. Available from: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19205> 2. Fraser C, Donnelly CA, Cauchelmes S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Published 11 May 2009 on Science Express. DOI: 10.1126/science.1176062. Available from: <http://www.sciencemag.org/cgi/content/abstract/1176062> 3. Rambaut A. Human/Swine A/H1N1 flu outbreak - BEAST analysis. Available from: <http://tree.bio.ed.ac.uk/groups/influenza/wiki/178c5/BEAST_Analysis_29_Apr_2008_-_Andrew_Rambaut.html> 4. Chowell G, Miller MA, Viboud C. Seasonal influenza in the United States, France, and Australia: transmission and prospects for control. Epidemiol Infect 2008; 136(6): 852-64. 5. Keeling MJ, Eames KT. Networks and epidemic models. J R Soc Interface 2005; 2(4): 295-307. [byline: D Coulombier and J Giesecke At: European Centre for Disease Prevention and Control, Stockholm, Sweden] -- communicated by: ProMED-mail <promed@promedmail.org> ****** [3] Date: Sat 9 May 2009 Source: The Veterinary Record, May 9 2009 [abbreviated and edited] <http://veterinaryrecord.bvapublications.com/cgi/content/full/164/19/577> [subscription required] Novel H1N1 influenza in people: global spread from an animal source? -------------------------------------------------------------------- The rapidly unfolding and evolving events, on a worldwide scale, relating to the human-to-human transmission of a novel H1N1 influenza A virus have dominated the news media in the past 2 weeks. In Europe to date, as in North America and Canada, there have been cases of laboratory-confirmed H1N1 infection in people returning from recent foreign travel in South America, specifically Mexico. In the vast majority of cases in people who are not from Mexico, the reported clinical presentation has been mild. Nevertheless, the emergence of this novel H1N1 influenza virus, and its rapid and worldwide spread, facilitated by the normal movement of people across international boundaries, highlights some important epidemiological features. It is relevant to note that while this H1N1 influenza virus has been termed "swine influenza" (or "swine flu"), the definitive scientific evidence base to support its origin in pig populations has not yet been confirmed. Furthermore, in the absence of contemporaneous reports of clinical disease in pigs infected with this virus, it is not possible to confirm the clinical signs that may be observed in infected animals. In common with other influenza A infections of pigs, where a range of clinical presentations can occur, asymptomatic infection with this virus is also a theoretical possibility. Epidemiology ------------ The epidemiology of swine influenza in pigs is itself not straightforward. However, a number of consistent features exist: -- swine influenza is an important, contagious disease of pigs that occurs worldwide, and is typically caused by infection with influenza A viruses; -- virus subtypes H1N1, H1N2 and H3N2 are endemic in many pig populations around the world, and pigs serve as major reservoirs of these viruses; -- interspecies transmission, including zoonotic infections, with the recognised endemic swine influenza viruses does occasionally occur (reviewed by Brown 2000). The maintenance of these influenza viruses in pigs, and the frequent introduction of new influenza viruses from other species, could, therefore, contribute to the generation of strains of human influenza virus with pandemic potential (Alexander and Brown 2000). Historical evidence of this suggests that, to date, the risk has been low. In addition, there is significant genetic and antigenic variability within each of the endemic swine influenza subtypes, which can often be dependent on geographical region. More specifically, before the emergence of this novel H1N1 virus, there has been a clear genetic distinction between North American and Eurasian lineages of swine influenza viruses. This new variant of H1N1 virus contains 3 of 8 gene segments (encoding for the neuraminidase and matrix protein genes) that do not appear typical of the genes seen in current North American strains. It has been postulated that these 3 gene segments have derived from Eurasian swine influenza viruses. It is not known if the particular genotype of H1N1 virus that appears putatively to have originated in Mexico is circulating in North American pigs, but its close similarity to other strains of swine influenza known to be circulating in the region (sharing 6 of 8 gene segments) has led to the assumption that this novel H1N1 strain is derived from pigs. [insert in text: Influenza A virus ecology with relevance to swine Influenza A viruses -------------------------------------------------------------------------------------- Influenza A viruses infect a large variety of animal species, including mammals and birds, and, given the worldwide animal-human interface, there is potential for interspecies transmission of influenza viruses in nature. Phylogenetic studies of influenza A viruses have revealed species-specific lineages of viral genes and have also demonstrated the frequency of interspecies transmision depends on the animal species. Aquatic birds are known to be the source of all influenza viruses for other species. Pigs are an important host in influenza virus ecology as they are susceptible to infection with both avian- and human-origin influenza A viruses, and are often involved in interspecies transmission, facilitated by regular close contact with people and/or birds. Following transmission to and independent spread of avian or human influenza viruses in pigs, these viruses are general referred to as being "avian-like" or "human-like" swine influenza viruses, reflecting both their previous and current hosts. After reassortment with other influenza A viruses, some of the genes of these viruses may be maintained in the resulting progeny viruses. Therefore, the evolution of influenza genes in species-specific lineagesis an invaluable characteristic in studying and determining influenza virus epidemiology.] Influenza viruses in pigs in Europe ----------------------------------- A number of countries in Europe conduct routine surveillance of pig populations for swine influenza, but, as this is not a notifiable disease in the EU, the surveillance programme is not consistent across the region. A European Swine Network for Influenza in Pigs (ESNIP2), funded by the EU, has been proactively monitoring the influenza situation in the European pig population for several years, and has demonstrated that subtypes H1N1, H3N2 and H1N2 co-circulate. There are also some significant differences in epidemiology in terms of the virus subtypes involved within the EU. For example, currently in Great Britain (GB) "avian-like" swine H1N1 viruses co-circulate with H1N2, but H3N2 has apparently disappeared since the mid-1990s [Data tabulated in the original text]. This is in contrast, for example, to the situation in Italy, where these viruses are still widespread (Van Reeth and others 2008). The genotypic diversity of the influenza viruses in the European pig population is also well recognised, and periodically genotypic variants are identified. However, broadly, the endemic strains retain common genotypes and the new reassorted variants appear to have poor viability for long-term sustainability and transmission within the swine population (Brown 2008). This is in contrast to the current situation in North America, where multiple genotypes of several different subtypes have emerged within the past 10 years, creating a complex aetiology with respect to swine influenza in these populations. Based on current evidence from surveillance programmes in several European countries, the variant of H1N1 virus recently isolated in human beings has never been reported, and therefore does not appear to be present in the European pig population. Swine influenza surveillance in Great Britain --------------------------------------------- In Great Britain, the Veterinary Laboratories Agency (VLA) has run a national swine influenza scanning surveillance programme since 1991, funded by the Department for Environment, Food and Rural Affairs (DEFRA). This programme is targeted, based on clear criteria using a standardised case definition, selection algorithm and sampling protocol, and provides free-of-charge laboratory testing for the detection of swine influenza viruses in clinical samples from affected pigs submitted by veterinary surgeons to VLA regional laboratories (RLs) and Scottish Agricultural College (SAC) Veterinary Services. Further information can be found on the VLA website at <http://www.defra.gov.uk/vla/diseases/dis_si.htm>, or from local VLA *** RLs or SAC disease surveillance centres. It is important for vigilance to be maintained within both the swine and human sectors for the emergence or spread of the newly reported H1N1 virus. The recent report of human-to-pig transmission in Alberta, Canada, highlights the importance of reverse zoonosis, a recognised phenomenon in influenza virus epidemiology. Ongoing close liaison and collaboration is also occurring between the VLA and public health institutes and delivery agencies to ensure rapid and robust information exchange. Capacity for change ------------------- The global human-animal interface is complex and dynamic, with the potential for zoonotic transmission of known pathogens, variants thereof and emergent infectious agents. In turn, animal reservoirs and people, both with the capacity for rapid global movement and distribution in time and space (intrinsic properties of globalisation), face these shared infectious challenges, not forgetting the propensity of some pathogens for 2-way exchange between species. While the novel H1N1 influenza virus is assumed to be of animal origin, it is now clearly spreading between humans and has already entered the EU, as well as other parts of the world. However, to date, human-to-animal transmission has not been identified or reported by EU member states. The case of human-to-pig transmission in Canada followed contact of an infected occupationally exposed worker, apparently incubating H1N1 virus infection following return from travel to Mexico. It also seems inevitable that more human cases will be detected worldwide. It is important to note that the potential host range for this virus is currently unknown. Potential changes in the virus characteristics need to be closely monitored by both public health and veterinary institutes. The world is watching on as international scientific and sociopolitical efforts attempt to better understand and combat an historical foe with seemingly limitless capacity for change and variation, and to evade predictions -- the influenza virus. [byline: Richard Irvine and Ian Brown Veterinary Laboratories Agency] References ---------- 1. Alexander DJ, Brown IH. Recent zoonoses caused by influenza A viruses. OIE Scientific and Technical Review 2000; 19: 197-225. 2. Brown IH. The epidemiology and evolution of influenza viruses in pigs. Veterinary Microbiology 2000; 74: 29-46 3. Brown IH. The role of pigs in interspecies transmission. In: H-D Klenk, MN Matrosovich, J Stech (editors). Avian Influenza. Monogr Virol. Karger, 2008; 27: 88-100. 4. Van Reeth K, Brown IH, Darrwald R, Foni E, Labarque G, Lany P, et al. Seroprevalence of H1N1, H3N2 and H1N2 swine influenza viruses in seven European countries in 2002-2003. Influenza and Other Respiratory Viruses 2008; 2: 99-105. -- communicated by: ProMED-mail <promed@promedmil.org> [see also: Influenza A (H1N1) - worldwide (30): case counts 20090516.1831 Influenza A (H1N1) - worldwide (29) 20090515.1824 Influenza A (H1N1) - worldwide (28): case counts 20090515.1822 Influenza A (H1N1) - worldwide (27): case counts 20090514.1800 Influenza A (H1N1) - worldwide (26) 20090514.1798 Influenza A (H1N1) - worldwide (25): case counts 20090513.1785 Influenza A (H1N1) - worldwide (24): case counts 20090512.1772 Influenza A (H1N1) - worldwide (23) 20090511.1764 Influenza A (H1N1) - worldwide (22): case counts 20090511.1759 Influenza A (H1N1) - worldwide (21) 20090510.1749 Influenza A (H1N1) - worldwide (20): case counts 20090510.1741 Influenza A (H1N1) - worldwide (10): case counts 20090504.1675 Influenza A (H1N1) - worldwide 20090430.1636] .......................cp/ejp/sh *##########################################################* ************************************************************ ProMED-mail makes every effort to verify the reports that are posted, but the accuracy and completeness of the information, and of any statements or opinions based thereon, are not guaranteed. The reader assumes all risks in using information posted or archived by ProMED-mail. ISID and its associated service providers shall not be held responsible for errors or omissions or held liable for any damages incurred as a result of use or reliance upon posted or archived material. ************************************************************ Become a ProMED-mail Premium Subscriber at <http://www.isid.org/ProMEDMail_Premium.shtml> ************************************************************ Visit ProMED-mail's web site at <http://www.promedmail.org>. Send all items for posting to: promed@promedmail.org (NOT to an individual moderator). If you do not give your full name and affiliation, it may not be posted. Send commands to subscribe/unsubscribe, get archives, help, etc. to: majordomo@promedmail.org. For assistance from a human being send mail to: owner-promed@promedmail.org. ############################################################ ############################################################
  11. Yes, I have read about this- the child rape at Abu Ghraib - We can only hope that America does NOT ACT like it’s been somehow forcibly sucked back into a sealed horror-movie canister only to sit back with silent shamefulness and phlegmy evil- and do NOTHING but fanatize about their own foot fetish and walk around like a dazed alcoholic strolling through Oktoberfest- sort of like we did throughout the entire Bush Adminastration.
  12. Horrific New Torture Pictures Released MORE photographs have been leaked of Iraqi citizens tortured by US soldiers at the notorious Abu Ghraib prison on the outskirts of Baghdad. http://www.informationclearinghouse.info/article11923.htm
  13. You had me up until you mentioned death camps- I completely agree that whatever is “really going on” regarding “H1N1 or any of the other H1, H7, H2, H5- avian, bird, swine or human -yada yada yada- flu was absolutely created in a lab by our own government and I also agree it is going in a very strange direction- either to control the population- or forced vaccinations- but death camps? Perhaps that thought is just something- I don’t want to think about yet.
  14. Hummmmmm- and yet again...... International Society for Infectious Diseases <http://www.isid.org> Date: Tue 5 May 2009 Source: The Poultry Site [edited] <http://www.thepoultrysite.com/poultrynews/17685/bird-flu-found-at-another-tennessee-farm> Bird flu found at another Tennessee farm ---------------------------------------- Avian flu has been found at another poultry farm in Tennessee. It is a low-pathogenic form, and the flu virus is the same as that found last week [27 Apr 2009] at another farm in the state. Tennessee and federal authorities are investigating a Lincoln County poultry farm after tests found a strain of avian influenza virus, according to WATE [Channel 6 TV]. The Tennessee Agriculture Department said in a statement on 4 May 2009 that the strain poses minimal risk to human health and is not the strain associated with human and poultry outbreaks in other countries. Officials said the strain can cause slight illness in poultry. A preliminary test on 1 May 2009 indicated the possibility of avian flu on the farm. Additional testing was completed by the US Department of Agriculture. The farm provides breeding stock for poultry farms and none of the poultry have entered the food supply. State officials told WATE this is the same strain found on a poultry farm in Giles County last week [27 Apr 2009] but there is no apparent connection. -- communicated by: ProMED-mail rapporteur Mary Marshall [How fascinating that the strain appears to be the same yet there seems to be no connection. I wonder if there are personnel that are the same between these 2 operations? Are there any birds that have been traded? Is there access to any wild avians that could have passed the virus to these facilities? - Mod.TG The state of Tennessee in the Southern US can be located on the HealthMap/ProMED-mail interactive map at <http://healthmap.org/r/00bP>. - CopyEd.MJ] [see also: Avian influenza (LPAI), poultry - USA (03): (TN) 20090505.1682 Avian influenza (LPAI), poultry - USA (02): (KY), H7N9 20090408.1361 Avian influenza (LPAI), poultry - USA (KY): H7 20090405.1314] .................tg/mj/sh *##########################################################* ************************************************************ ProMED-mail makes every effort to verify the reports that are posted, but the accuracy and completeness of the information, and of any statements or opinions based thereon, are not guaranteed. The reader assumes all risks in using information posted or archived by ProMED-mail. ISID and its associated service providers shall not be held responsible for errors or omissions or held liable for any damages incurred as a result of use or reliance upon posted or archived material. ************************************************************ Become a ProMED-mail Premium Subscriber at <http://www.isid.org/ProMEDMail_Premium.shtml> ************************************************************ Visit ProMED-mail's web site at <http://www.promedmail.org>. Send all items for posting to: promed@promedmail.org (NOT to an individual moderator). If you do not give your full name and affiliation, it may not be posted. Send commands to subscribe/unsubscribe, get archives, help, etc. to: majordomo@promedmail.org. For assistance from a human being send mail to: owner-promed@promedmail.org. ############################################################ ############################################################
  • Create New...